Public Employees Retirement System of Ohio Cuts Position in IQVIA Holdings Inc. $IQV

Public Employees Retirement System of Ohio lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 40.0% during the first quarter, Holdings Channel reports. The fund owned 50,899 shares of the medical research company’s stock after selling 33,964 shares during the period. Public Employees Retirement System of Ohio’s holdings in IQVIA were worth $8,680,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Vanguard Group Inc. boosted its holdings in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Geode Capital Management LLC lifted its position in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares during the last quarter. Boston Partners boosted its stake in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares in the last quarter. Finally, Invesco Ltd. grew its position in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after acquiring an additional 367,204 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $212.76 on Tuesday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The firm has a market cap of $35.51 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. The business has a 50 day moving average price of $189.02 and a 200-day moving average price of $186.85.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the firm earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Evercore reissued an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Robert W. Baird raised their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.